There is convincing evidence, in animal models and in humans, that deep osteochondral defects of the joint surface lead to a high rate of osteoarthritis (OA) over time.
JOINTPROMISE paves
the way for high-volume, affordable production of entire biological
joints, addressing a major socioeconomic challenge of the European ageing society.
Taken together we strive to develop an automated, GMP-grade platform producing large, patterned and vascularised joint implants providing also a paradigm shift for generic automated manufacturing of organoid-based tissue implants.